 YAVNE, Israel, Dec. 14, 2020 GLOBE NEWSWIRE -- MediWound Ltd. Nasdaq: MDWD, a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group GAG, an international conglomerate based in the United Arab Emirates UAE, an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year. 